Cafestol
 |
|
|---|---|
| Systematic (IUPAC) name | |
| (3bS,5aS,7R,8R,10aR,10bS)-3b,4,5,6,7,8,9,10,10a,10b,11,12-Dodecahydro- 7-hydroxy-10b-methyl-5a,8-methano-5aH-cyclohepta[5,6]naphtho[2,1-b]furan-7-methanol |
|
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | Legal everywhere |
| Routes | Oral |
| Identifiers | |
| CAS number | 469-83-0 |
| ATC code | None |
| PubChem | CID 108052 |
| ChemSpider | 10289419 |
| UNII | AC465T6Q6W |
| KEGG | C09066 |
| Chemical data | |
| Formula | C20H28O3 |
| Mol. mass | 316.439 g/mol |
|
|
| Physical data | |
| Melt. point | 158–162 °C (316–324 °F) |
Cafestol is a diterpene molecule present in coffee.
A typical bean of Coffea arabica contains about 0.6% cafestol by weight. Cafestol is present in highest quantity in unfiltered coffee drinks such as French press coffee or Turkish coffee/Greek coffee. In filtered coffee drinks such as drip brewed coffee, it is present in only negligible amounts.
Studies have shown that regular consumption of boiled coffee increases serum cholesterol by 8% in men and 10% in women. For those drinking filter coffee, the effect was only significant for women.[1]
Clinical significance [edit]
Cafestol has also shown anticarcinogenic properties in rats.[1] Cafestol may act as an agonist ligand for the nuclear receptor Farnesoid X receptor and Pregnane X receptor, blocking cholesterol homeostasis.[2] Cafestol has also been implicated in inhibiting the progress of Parkinson's disease.[3]
See also [edit]
References [edit]
- ^ a b National Toxicology Program (NTP): Cafestol (CASRN 469-83-0) and Kahweol (CASRN 6894-43-5) - Review of Toxicological Literature. (PDF) October 1999
- ^ Ricketts ML, Boekschoten MV, Kreeft AJ, Hooiveld GJ, Moen CJ, Müller M, Frants RR, Kasanmoentalib S, Post SM, Princen HM, Porter JG, Katan MB, Hofker MH, Moore DD (July 2007). "The cholesterol-raising factor from coffee beans, cafestol, as an agonist ligand for the farnesoid and pregnane X receptors". Mol. Endocrinol. 21 (7): 1603–16. doi:10.1210/me.2007-0133. PMID 17456796.
- ^ Trinh K, Andrews L, Krause J, Hanak T, Lee D, Gelb M, Pallanck L (April 2010). "Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson's disease through an NRF2-dependent mechanism". J. Neurosci. 30 (16): 5525–32. doi:10.1523/JNEUROSCI.4777-09.2010. PMID 20410106. Lay summary – New Scientist.
|
|||||||||||||||||||||||||||||||||||
Media related to 
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
